Mirikizumab

Mirikizumab
Monoclonal antibody
Type?
SourceHumanized (from mouse)
Targetinterleukin 23A
Clinical data
Other namesLY3074828
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6380H9842N1686O2004S48
Molar mass143767.59 g·mol−1

Mirikizumab (INN;[1] development code LY3074828) is a human monoclonal antibody designed for the treatment of psoriasis.

This drug was developed by Eli Lilly and Co.[2] As of 2018, mirikizumab is undergoing Phase III trials.

References

  1. World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 117" (PDF). WHO Drug Information. 31 (2).
  2. Statement On A Nonproprietary Name Adopted By The USAN Council - Mirikizumab, American Medical Association.


This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.